TipRanks
Advertisement
Advertisement

DE:EX9 Stock Latest News

Exelixis Rated Hold as Zanzalintinib CRC Outlook Remains Mixed; $54 Price Target Reaffirmed
RatingsExelixis Rated Hold as Zanzalintinib CRC Outlook Remains Mixed; $54 Price Target Reaffirmed
20d ago
EXEL
FDA-Driven Zanza Delay Keeps Exelixis Fairly Valued, Supporting Willey’s Hold Rating
PremiumRatings
FDA-Driven Zanza Delay Keeps Exelixis Fairly Valued, Supporting Willey’s Hold Rating
22d ago
EXEL
Exelixis risk of rejection ‘low’ despite zanzalintinib delay, says William Blair
PremiumThe Fly
Exelixis risk of rejection ‘low’ despite zanzalintinib delay, says William Blair
23d ago
EXEL
FDA Extends Review Timeline for Exelixis Cancer Drug
PremiumCompany Announcements
FDA Extends Review Timeline for Exelixis Cancer Drug
23d ago
8K
EXEL
Exelixis says FDA extends review period for zanzalintinib NDA by three months
PremiumThe Fly
Exelixis says FDA extends review period for zanzalintinib NDA by three months
23d ago
EXEL
Adagene announces $2M milestone payment from Exelixis
PremiumThe FlyAdagene announces $2M milestone payment from Exelixis
25d ago
ADAG
EXEL
Exelixis Secures Key Patent Victory, Extends Exclusivity
Premium
Company Announcements
Exelixis Secures Key Patent Victory, Extends Exclusivity
1M ago
8K
EXEL
Exelixis says appeals court affirmed ‘key portion’ of 2024 judgment
Premium
The Fly
Exelixis says appeals court affirmed ‘key portion’ of 2024 judgment
1M ago
EXEL
Trump Trade: U.S. considering new semiconductor tariffs
PremiumThe Fly
Trump Trade: U.S. considering new semiconductor tariffs
1M ago
MU
AMD
White House to announce drug pricing deals with biotechs, Bloomberg reports
PremiumThe Fly
White House to announce drug pricing deals with biotechs, Bloomberg reports
1M ago
ALKS
ALNY
BMO starts Exelixis at Market Perform into patent cliff
PremiumThe Fly
BMO starts Exelixis at Market Perform into patent cliff
2M ago
EXEL
Exelixis initiated with a Market Perform at BMO Capital
PremiumThe Fly
Exelixis initiated with a Market Perform at BMO Capital
2M ago
EXEL
Exelixis Earnings Call: Cabo Strength, Zanza Awaited
PremiumCompany AnnouncementsExelixis Earnings Call: Cabo Strength, Zanza Awaited
2M ago
EXEL
Leerink downgrades Exelixis to Market Perform following Q2 results
Premium
The Fly
Leerink downgrades Exelixis to Market Perform following Q2 results
2M ago
EXEL
Exelixis downgraded to Market Perform from Outperform at Leerink
Premium
The Fly
Exelixis downgraded to Market Perform from Outperform at Leerink
2M ago
EXEL
Exelixis price target raised to $51 from $47 at Stifel
PremiumThe Fly
Exelixis price target raised to $51 from $47 at Stifel
2M ago
EXEL
Exelixis price target lowered to $52 from $56 at Truist
PremiumThe Fly
Exelixis price target lowered to $52 from $56 at Truist
2M ago
EXEL
Exelixis: Buy Rating Reaffirmed on Cabozantinib Resilience, Cost Discipline and Zanzalintinib Upside Despite Near-Term NET Guidance Cut
PremiumRatings
Exelixis: Buy Rating Reaffirmed on Cabozantinib Resilience, Cost Discipline and Zanzalintinib Upside Despite Near-Term NET Guidance Cut
2M ago
EXEL
Exelixis reports Q2 non-GAAP EPS 91, consensus 86c
PremiumThe Fly
Exelixis reports Q2 non-GAAP EPS 91, consensus 86c
2M ago
EXEL
Exelixis lowers FY26 revenue outlook to $2.5B-$2.55B from $2.525B-$2.625B
PremiumThe FlyExelixis lowers FY26 revenue outlook to $2.5B-$2.55B from $2.525B-$2.625B
2M ago
EXEL
EXEL Earnings this Week: How Will it Perform?
Premium
Pre-Earnings
EXEL Earnings this Week: How Will it Perform?
2M ago
EXEL
Exelixis price target raised to $53 from $50 at Morgan Stanley
Premium
The Fly
Exelixis price target raised to $53 from $50 at Morgan Stanley
2M ago
EXEL

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >